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Available online 10 February 2016Small interfering RNA (siRNA) screening approaches have provided useful tools for the validation of genetic
functions; however, image-based siRNA screening using multiwell plates requires large numbers of cells and
time, which could be the barrier in application for gene mechanisms study using human adult cells. Therefore,
we developed the advanced method with the cell-deﬁned siRNA microarray (CDSM), for functional analysis of
genes in small scale within slide glass using human bone marrow stromal cells (hBMSCs).
We designed cell spot system with biomaterials (sucrose, gelatin, poly-L-lysine and matrigel) to control the
attachment of hBMSCs inside spot area on three-dimensional (3D) hydrogel-coated slides. The p65 expression
was used as a validation standard which described our previous report. For the optimization of siRNA mixture,
ﬁrst, we detected ﬁve kinds of commercialized reagent (Lipofectamine 2000, RNAi-Max, Metafectine,
Metafectine Pro, TurboFectin 8.0) via validation. Then, according to quantiﬁcation of p65 expression, we selected
2 μl of RNAi-Max as the most effective reagent condition on our system. Using same validation standard, we
optimized sucrose and gelatin concentration (80 mM and 0.13%), respectively. Next, we performed titration of
siRNA quantity (2.66–5.55 μM) by reverse transfection time (24 h, 48 h, 72 h) and conﬁrmed 3.75 μM siRNA con-
centration and 48 h as the best condition. To sum up the process for optimized CDSM, 3 μl of 20 μM siRNA
(3.75 μM) was transferred to the 384-well V-bottom plate containing 2 μl of dH2O and 2 μl of 0.6 M sucrose
(80 mM). Then, 2 μl of RNAi-Max was added and incubated for 20 min at room temperature after mixing gently
and centrifugation shortly. Five microliters of gelatin (0.26%) and 2 μl of growth factor reduced phenol red-free
matrigel (12.5%) were added and mixed by pipetting gently. Finally, optimized siRNA mixture was printed on
3D hydrogel-coated slides and cell-deﬁned attachment and siRNA reverse transfection were induced.
The efﬁciency of this CDSMwas veriﬁed using three siRNAs (targeting p65, Slug, and N-cadherin), with persistent
gene silencing for 5 days.We obtained the signiﬁcant and reliable datawith effective knock-down in our condition,
and suggested our method as the qualitatively improved siRNA microarray screening method for hBMSCs.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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RNA interference (RNAi), which induces the knockdown of speciﬁc
genes by binding to complementary sequences of mRNA transcripts
to promote mRNA degradation, was ﬁrst developed for post-
transcriptional silencing in Caenorhabditis elegans. Since then, RNAi
screening has been used as a tool for functional genomic studies intitute and IRICT, Center for Cell
01 Daehak-ro, Jongro-gu, Seoul
ra, Strasbourg 67000, France.
ipk@gmail.com (Y.-J. Kwon).
67000, France.
. This is an open access article undermammalian cells. RNAi screening facilitates the identiﬁcation of genes
associated with a given pathway by silencing speciﬁc genes and has
been shown to have applications in a variety of ﬁelds, including cell
signaling, cancer, and infectious disease (Seyhan and Ryan, 2010;
Cherry, 2009; Fire et al., 1998; Iorns et al., 2008; Luo et al., 2009;
Prudêncio and Lehmann, 2009; Scholl et al., 2009).
Reverse transfection cell microarrays have been developed as a new
high-throughput system following the reporting of the lipid-DNAmeth-
od (LDM) (Wheeler et al., 2005; Stürzl et al., 2008; Kittler et al., 2007;
Genovesio et al., 2011a, 2011b; Erﬂe et al., 2007; Castel et al., 2006;
Stürzl et al., 2008; Ziauddin and Sabatini, 2001). This method allows
for reduced screening time, rapid analysis, and visualization of cell phe-
notype and is therefore advantageous over more traditional screening
methods. Moreover, many investigators have adapted this concept tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cell types and various transfection reagents, such as Lipofectamine
2000, lipofectin, effectene, and culture surfaces coated with amino
silane (GAPS) and poly-L-lysine (PLL) (Erﬂe et al., 2007; Baghdoyan
et al., 2004; Kumar et al., 2003; Mousses et al., 2003; Redmond et al.,
2004; Silva et al., 2004; Webb et al., 2003). We also developed an
siRNA microarray system using Lipofectamine 2000 and PLL-coated
coverslips for automated genome-wide visual proﬁling of cellular pro-
teins involved in human immunodeﬁciency virus (HIV) infections and
identiﬁcation of human-host factors associated with Trypanosoma
cruzi infection (Genovesio et al., 2011a, 2011b). However, in these
siRNAmicroarrays, siRNA spreading between spot and spot is observed
in cells that exhibit mobility, such as human bonemarrow stromal cells
(hBMSCs),whichhave an elongated cell shape and showhighmigration
activity (Supplemental Fig. 1). In addition to these limitations, it is also
difﬁcult to obtain sufﬁcient numbers of hBMSCs for high-throughput
screening assays. Therefore, despite the necessity for additional studies
of the functions of genes in hBMSCs, siRNA microarrays or similar
methods are not commonly used for functional genomics studies.
In this study, we present the other method, the cell-deﬁned siRNA
microarray (CDSM), which was designed to restrict the culture of
hBMSCs inside the spot area without reducing the efﬁciency of siRNA
silencing. This CDSM technology may be applicable for functional
genomic studies with limited numbers of cells and is expected to pro-
vide efﬁcient method for siRNA screening.
2. Materials and methods
2.1. hBMSCs culture
hBMSCs were purchased from Lonza (Basel, Switzerland). The cells
were cultured in MSC basal medium (MSCBM; Lonza), supplemented
with BMSC growth medium (MSCGM), an hBMSCs SingleQuots kit
(Lonza), 5% fetal bovine serum, 1% L-glutamine, and 0.1% GA-1000.
Cultures were maintained at 37 °C in a humidiﬁed cell incubator with
an atmosphere of 5% CO2, and the culture medium was changed twice
per week.
2.2. Optimization of the siRNA solution
We used p65 protein expression, a component of the NF-kB com-
plex, as validation control because its silencing could be easily estimated
by immunoﬂuorescence staining (Genovesio et al., 2011b), and
conﬁrmed p65 protein expression of hBMSCs before optimization of
CDSM. The basic mixing method for the siRNA solution was described
previously (Genovesio et al., 2011a, 2011b; Rantala et al., 2011). For
biomaterials selection, 2 μl of 20 μM scramble siRNA, 2.66 μM as ﬁnal
concentration, was transferred to the 384-well V-bottom plate (Greiner
Bio-one) containing 0 μl to 7 μl of dH2O with 2 μl of 0.8 M sucrose,
106 mM as ﬁnal concentration (Invitrogen, Carlsbad, CA, USA) diluted
in Opti-MEM (Gibco, USA) or without sucrose following conditions.
Two microliters of Lipofectamine 2000 was added and the solution
was mixed gently. The complexes of siRNA and transfection reagent
were incubated for 20 min at room temperature after centrifugation
(1200 rpm, 30 s). Five microliters of gelatin (diluted in dH2O, 0.26%
ﬁnal concentration; Invitrogen) and 2 μl of PLL (diluted in dH2O,
0.0053% ﬁnal concentration; Sigma) were added; not following
conditions, 2 μl of growth factor reduced phenol red-free matrigel (BD
Biosciences, USA) was added; or not following conditions, all solution
was mixed by pipetting. The detailed information such as ﬁnal concen-
tration was summarized in Table 1.
For the selection of transfection reagent, 2 μl of 20 μMsiRNA, 2.66 μM
as ﬁnal concentration (scramble and p65 siRNA as a smart pool of four
individual siRNAs per target; Dhamacon) was transferred to the
384-well V-bottom plate (Greiner Bio-one) containing 2 μl of dH2O
and 2 μl of 0.8 M sucrose, 106 mM as ﬁnal concentration (Invitrogen,Carlsbad, CA, USA) diluted in Opti-MEM (Gibco, USA). Each 2 μl of trans-
fection reagents (Lipofectamine 2000, RNAi-Max [Invitrogen, USA];
Metafectine, Metafectine Pro [Biontex, Germany], and TurboFectin 8.0
[OriGene, USA]) was added, and the solution was mixed gently. The
complexes containing siRNA and transfection reagent were incubated
for 20 min at room temperature after centrifugation (1200 rpm, 30 s).
Five microliters of gelatin (diluted in dH2O, 0.26% ﬁnal concentration;
Invitrogen) and 2 μl of growth factor reduced phenol red-free matrigel
(BD Biosciences, USA) were added and mixed gently by pipetting.
For the validation of transfection reagent volume, 2 μl of 20 μM
scramble and p65 siRNA (2.5 μM, 2.66 μM and 2.85 μM as ﬁnal concen-
tration) was transferred to the 384-well V-bottom plate containing 2 μl
of dH2O and 2 μl of 0.8 M sucrose (100 mM, 106 mM and 114 mM as
ﬁnal concentration) diluted in Opti-MEM. Each 3 μl, 2 μl and 1 μl of
RNAi-Max was added and then the solution was mixed gently. The
complexes containing siRNA and transfection reagent were incubated
for 20 min at room temperature after centrifugation (1200 rpm, 30 s).
Five microliters of gelatin diluted in dH2O (0.25%, 0.26% and 0.28% as
ﬁnal concentration; Invitrogen) and 2 μl of growth factor reduced
phenol red-free matrigel (BD Biosciences, USA) were added and
mixed gently by pipetting.
For the validation of sucrose and gelatin, 2 μl of 20 μM scramble and
p65 siRNA (2.66 μM as ﬁnal concentration) was transferred to the 384-
well V-bottomplate containing 2 μl of dH2O and each 2 μl of 1.6M, 0.8M
and 0.6M sucrose (213mM, 106mMand80mMasﬁnal concentration)
diluted in Opti-MEM. Twomicroliters of RNAi-Maxwas added and then
the solution was mixed gently. The complexes containing siRNA and
transfection reagent were incubated for 20 min at room temperature
after centrifugation (1200 rpm, 30 s). Five microliters of 0.8% and 0.4%
gelatin diluted in dH2O (0.26% and 0.13% as ﬁnal concentration) and
2 μl of growth factor reduced phenol red-free matrigel (BD Biosciences,
USA) were added and mixed gently by pipetting.
For the validation of siRNA volume and reverse transfection time, each
2 μl to 5 μl of 20 μM scramble and p65 siRNA (2.66 μM, 3.75 μM, 4.7 μM
and 5.55 μM as ﬁnal concentration) was transferred to the 384-well V-
bottom plate containing 2 μl of dH2O and each 2 μl of 0.6 M sucrose
(80mM, 75mM, 70.58mMand 66.66mMas ﬁnal concentration) diluted
in Opti-MEM. Twomicroliters of RNAi-Maxwas added and then the solu-
tion was mixed gently. The complexes containing siRNA and transfection
reagent were incubated for 20min at room temperature after centrifuga-
tion (1200 rpm, 30 s). Five microliters of 0.4% gelatin diluted in dH2O
(0.13%, 0.12% and 0.11% as ﬁnal concentration) and 2 μl of growth factor
reduced phenol red-free matrigel (BD Biosciences, USA) were added
and mixed gently by pipetting.
After each all step, the solution was mixed gently and centrifuged
(1200 rpm, 30 s). The summarized information was shown in Table 2.
2.3. Printing for CDSM
Three-dimensional (3D) hydrogel-coated slides (H; 25 × 75.6 ×
1mm; SCHOTT) were held at room temperature for 30 min to 1 h before
opening the packaging bag; this step is very important for achieving qual-
ity microarray results because chilled slides generate moisture on the
surface, leading to fur forms. The prepared siRNA transfection solution
was printed on the 3D hydrogel-coated slide using SMP9 stealth pins
(Telechem, Atlanta, GA, USA) and a high-throughput microarray printer
(Genomic Solutions, AnnArbor,MI, USA) at 22–25 °C and 55–60% relative
humidity. Printed spots were 250–350 μm in diameter with a 700 μm
spot-to-spot interval. The prepared CDSMs were dried in a desiccating
chamber overnight, packaged in airtight bags, and then stored at 4 °C
until further use.
2.4. hBMSCs preparation and culture on the CDSMs
Vials of hBMSCs stored in liquid nitrogen (LN2) tankwere thawed in
25 T or 75 T ﬂasks and then cultured for 1 week to reach 70%–80%
367H.C. Kim et al. / Stem Cell Research 16 (2016) 365–376conﬂuence. The prepared cells (2 × 105 cells/4ml/slide) detached by in-
cubation with 0.05% trypsin–EDTA (Gibco) were seeded on CDSMs
whichwere removed frommoisture and transferred to a 4-well rectan-
gular dish (Nunc, USA). Cell attachment was induced for 10 min, and
unattached cells were removed by washing 3–5 times with fresh
hBMSCs medium. Even after incubation of unattached cells for more
than 24 h without washing, no cell attachment was observed on the
slide surface outside of the spots (data not shown). The hBMSCsFig. 1. Schematic of the development of the hBMSCs microarray. (A) Printing of the optimal s
(B) Seeding and culture for 10 min to induce attachment of cells on the spots. (C) Removal of
spot-cultured hBMSCs. (E) Image acquisition and analysis using an ImageXpress Ultra Point s
acquired with two ﬂuorescent channels, which were ﬁltered with Alexa 488 for green ﬂuoresc
of ﬂuorescently stained cells, which was calculated by measuring the ﬂuorescence intensity, ceattached on the spot region were cultured for 1–7 days to induce
reverse transfection. The medium was refreshed every 48 h.
2.5. Immunoﬂuorescence staining
The immunoﬂuorescence staining of hBMSCs on CDSMs was
performed using standard methods. The cells were washed with 1×
phosphate-buffered saline (PBS) once and ﬁxed with 4% (w/v)iRNA solution using a high-throughput microarray printer on 3D hydrogel-coated slides.
unattached cells by washing gently with fresh media. (D) The delivery of siRNA into the
canning confocal microscope and MetaXpress software. The image of the cell spots was
ence and 635 nm for Draq5. The image was analyzed by measurement of the proportion
ll number, and cell size.
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with 1× PBS and permeabilized with 0.001% Triton-X100 in 1× PBS for
10 min. Primary antibodies targeting CD105 (1:200 dilution; mouse
monoclonal; Santa Cruz Biotechnology, CA, USA), CD29 (1:100 dilution;
mouse monoclonal; Merck Millipore), CD14 (1:200 dilution; mouse
monoclonal; Santa Cruz Biotechnology, CA, USA), CD34 and CD45
(1:200 dilution; rabbit polyclonal; Santa Cruz Biotechnology, CA, USA),
p65 (1:400 dilution; rabbit polyclonal; Santa Cruz Biotechnology),
Slug (1:200 dilution; rabbit monoclonal; Cell Signaling Technology,
Beverly, MA, USA), N-cadherin (1:1600 dilution; mouse monoclonal;
Santa Cruz Biotechnology), β-catenin (1:100 dilution; rabbit monoclo-
nal; Cell Signaling Technology), normal mouse and rabbit IgG (1;100
dilution; unconjugated, afﬁnity puriﬁed isotype control immunoglobulinFig. 2. Optimization of biomaterials for the cell-deﬁned array. (A) Immunoﬂuorescence and phas
cell-friendly substances. (B) Quantitative analysis of cell numbers in (A) using MetaXpress softw
ImageXpress Ultra Point scanning confocal microscope with anti-p65 antibodies. Blue: nuclei sta
themean± SD. ⁎⁎p b 0.01, ⁎⁎⁎p b 0.001: statistical signiﬁcance of comparisons between sucrose/gefrom mouse and rabbit; Santa Cruz Biotechnology) were diluted with
10% goat serum in 1× PBS. Primary antibodies targeting CD73 (1:200 di-
lution; goat polyclonal; Santa Cruz Biotechnology) and normal goat IgG
(1;100 dilution; unconjugated, afﬁnity puriﬁed isotype control immuno-
globulin from goat; Santa Cruz Biotechnology) were diluted with 1%
bovine serum albumin (BSA) in 1× PBS. All primary antibody incubations
were performed for 1.5 h at room temperature. Afterwashing three times
with 1× PBS, secondary goat anti-rabbit or goat anti-mouse antibodies
conjugated with Alexa 488 were diluted with 10% goat serum in 1×
PBS, and donkey anti-goat antibodies conjugated with Alexa 568 were
diluted with 1% BSA in 1× PBS (1:1000 dilution; Invitrogen). Secondary
antibody incubations were performed for 1.5 h at room temperature.
After washing three times with 1× PBS, 5 mM DRAQ5 (1:2000 in PBS;e-contrast images of cells cultured for 48 h on scramble siRNA spots, which included various
are and condition of substances solution (right table). The images were obtained using an
ined with Draq5; green: ﬂuorescently labeled anti-p65 antibodies. Each error bar represents
latin, matrigel medium and others (representative of n=9 array spots, scale bar=100 μm).
369H.C. Kim et al. / Stem Cell Research 16 (2016) 365–376Biostatus, UK)was added, and sampleswere incubated for 10min to stain
the nuclei. After rinsing with 1× PBS, 2–3 drops of mounting solution
(Dako, France) was added to the CDSM, and the slides were covered
with glass coverslips (24 × 60 mm; Marienfeld, Germany), ensuring
that therewereno air bubbles. Slideswere thendried for 1h at room tem-
perature. After ﬁxing with mounting solution, the CDSMs were stored at
4 °C until image acquisition.Fig. 3. Selection of optimal siRNAquantity and transfection time. (A) Immunoﬂuorescence image
for 48 h (n = 9 array spots, scale bar =100 μm). (B) Ampliﬁed image for cells transfected
(D) Immunoﬂuorescence image of p65 gene expression knockdown efﬁciency according to tr
ratio of p65-positive cells in (D). Images were obtained using an ImageXpress Ultra Point sc
green: ﬂuorescently labeled anti-p65 antibodies. Scrambled siRNA was used as a control. T
mean ± SD. ⁎⁎⁎p b 0.001: statistical signiﬁcance of comparisons with scrambled siRNA; †††p b 02.6. Image acquisition and analysis
Immunoﬂuorescence imagingwas performed using an ImageXpress
Ultra Point scanning confocal microscope (Molecular Devices, USA)
equipped with four solid-state lasers for simultaneous excitation
at 405, 488, 561, and 635 nm; a galvanometer for X scanning; and a
stage for Y scanning. Each cell spot was scanned at 10× or 20×ofp65 gene expression knockdown efﬁciency according to the concentration of p65 siRNA
with 3.75 μM siRNA. (C) Quantitative analysis of the ratio of p65-positive cells in (A).
ansfection time (n = 9 array spots, scale bar =100 μm). (E) Quantitative analysis of the
anning confocal microscope and anti-p65 antibodies. Blue: nuclei stained with Draq5;
he analysis was performed using MetaXpress software. Each error bar represents the
.001: statistical signiﬁcance of comparisons among p65 siRNA concentrations.
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ﬁlter sets for Alexa488, Alexa568, and Alexa635. The acquired images
were analyzed with MetaXpress software (Molecular Devices). Cell
scoring parameters were also determined to evaluate the proportion
of ﬂuorescent-positive cells, which was calculated according to the
ﬂuorescence intensity, nuclei numbers, and size (Fig. 1, Supplemental
Fig. 2). GraphPad Prism 5 software was used to determine statistical
signiﬁcance for comparisons of two groups by one-way or two-
way analysis of variance (ANOVA) and the Bonferroni method. Differ-
ences with p values of less than 0.05 were considered statistically
signiﬁcant.
3. Results
3.1. Establishment of the CDSM
To develop the CDSM, we selected 3D hydrogel-coated slides coated
with amine-reactive NHS ester groups as hydrophobic slides with cell-
resistant properties. We then attempted to culture hBMSCs on the
siRNA spots printed on the slide surface. Because sucrose/gelatin, PLL,
and matrigel have been shown to affect the adherence and growth of
cells (Genovesio et al., 2011a, 2011b; Rantala et al., 2011), we tested var-
ious combinations of these reagents to determine the optimal mixture.
Low cell attachment and irregularly shaped cellswere observed in culture
without sucrose/gelatin or matrigel, and PLL did not signiﬁcantly
inﬂuence the adhesion of hBMSCs. Therefore, we chose an appropriate
combination of sucrose/gelatin and matrigel for spot-deﬁned hBMSCs
attachment and culture (Fig. 2).
We also optimized the transfection reagent for achieving effective
siRNA-mediated gene silencing by printing of p65 siRNA solutions com-
bined with different transfection reagents. Three of the reagents
showed increased knockdown efﬁciency of p65 siRNA; RNAi-Max had
the most substantial effect among the reagents (Supplemental Fig. 3).
For conﬁrmation of the appropriate volume of RNAi-Max, three
different volumes (1, 2, and 3 μl) were tested with 2 μl of p65 siRNA
(RNAi-Max vs. siRNA, 1 μl vs. 2.85 μM, 2 μl vs. 2.66 μM, 3 μl vs.
2.5 μM). Signiﬁcant knockdown efﬁciencywas observed at low volumes
(i.e., 1–2 μl) when comparedwith RNAi-Max (3 μl). Therefore, we chose
2 μl of RNAi-Max as the optimum volume because the stability of siRNA
knockdown with only 1 μl of RNAi-Max was uncertain (Supplemental
Fig. 4A and B).
Sucrose and gelatin are known to be cell-friendly biomaterials;
hence, these were used along with matrigel for spot-deﬁned culture
(Fig. 2). This combination of sucrose/gelatin and matrigel facilitated
cell attachment on the siRNA spot, promoted the formation of circular
spots after printing, protected the spots from being washed away by
the medium, and inﬂuenced the transfection efﬁciency. However,
higher concentrations may cause spreading of spots and ineffective
printing due to high viscosity.Moreover, low concentrations sometimes
decrease the knockdown efﬁciency of the siRNA spot. Therefore, weTable 1
The condition of printing solution for biomaterials selection.
Substances Figure
Fig. 2-I Fig. 2-II
Scramble 2 μl [2.66 μM] 2 μl [2.66 μM]
Lipofectamine2000 2 μl [13.3%] 2 μl [13.3%]
Sucrose (0.8 M) 2 μl [106 mM] 2 μl [106 mM]
Gelatin (0.8%) 5 μl [0.26%] 5 μl [0.26%]
Matrigel 2 μl [13.3%] –
PLL (0.04%) 2 μl [0.0053%] –
RNase-free water – 4 μl [26.6%]
Total volume 15 μl 15 μl
(): Stock concentration.
[]: Final concentration. The numbers from second places of decimals are ignored.performed experiments to determine the optimal concentrations of su-
crose and gelatin. Our results showed that p65 siRNA provided efﬁcient
knockdown independent of the concentrations of sucrose and gelatin.
Moreover, higher concentrations of sucrose and gelatin (1.6 M/0.8%
and 0.8M/0.8%) caused inefﬁcient printing (withmissed spots or varia-
tions in spot shape/size). From this analysis, we chose the combination
of 0.6 M sucrose and 0.4% gelatin (Supplemental Fig. 4C and E).
For high-efﬁciency delivery of lipid-based siRNA to cells, the ratio of
siRNA to transfection reagent in the mixture is an important factor.
From our results described above, we found that 2 μl of RNAi-Max was
optimal. Therefore, we next examined the optimal ratio of RNAi-Max
to p65 siRNA for various transfection times. The knockdown efﬁciency
of p65 siRNA was signiﬁcant at all the siRNA concentrations and time
conditions except for 2.66 μM p65 siRNA for 72 h. The efﬁciency was
increased dramatically under conditions of more than 3.75 μM siRNA
with a 48 h transfection time (Fig. 3, Supplemental Fig. 5).
3.2. Conﬁrmation of hBMSCs localization and characterization on CDSM
slides
Next, we conﬁrmed the optimization of the CDSM according to the
optimal parameters described above (Figs. 2 and 3, Supplemental Figs.
3–5, Table 1). The characteristics of hBMSCs cultured for 10 min, 1 h,
or 48 h on the deﬁned spot areas containing non-targeting siRNA
were conﬁrmed. Bright-ﬁeld images showed that hBMSCs grew and
hBMSCs-speciﬁc makers were expressed speciﬁcally (CD105, CD29,
and CD73) or negative expressed (CD14, CD34, and CD45) in hBMSCs
(Fig. 4, Supplemental Fig. 6).
3.3. Conﬁrmation of the knockdown efﬁciency of target genes
For validation of the CDSM, we ﬁrst attempted to conﬁrm siRNA-
mediated knockdown of other target genes that are expressed in
hBMSCs. To this end, we examined the knockdown of the nuclear factor
(NF) kappa B subunit (p65), the mesenchymal cell maker N-cadherin
(NCAD), and the zinc ﬁnger transcription factor (Slug) in the newly op-
timized CDSM. All three genes were signiﬁcantly down regulated by
more than 70% (Fig. 5A-C). To further support the use of CDSM as a
tool for functional genomic studies of hBMSCs, we investigated the ex-
pression levels of proteins related to NCAD, with a focus on β-catenin,
which is involved in the regulation of cell–cell adhesion, gene transcrip-
tion, and intracellular signal transduction in theWnt signaling pathway.
β-Catenin expression has been shown to be slightly decreased following
suppression of N-cadherin expression in HEK293 cells (Howard et al.,
2011). Indeed, we found decreased expression of β-catenin on printed
N-cadherin siRNA spots on the CDSM (Fig. 5D).
We further examined the knockdown of NCAD by siRNA using a
multispot assay developed by printing of a total of 128 spots. All NCAD
siRNA spots showed an average of 70% knockdown of NCAD, with
approximately 10–15% variation in efﬁciency. The average number ofFig. 2-III Fig. 2-IV Fig. 2-V
2 μl [2.66 μM] 2 μl [2.66 μM] 2 μl [2.66 μM]
2 μl [13.3%] 2 μl [13.3%] 2 μl [13.3%]
2 μl [106 mM] – 2 μl [106 mM]
5 μl [0.26%] – 5 μl [0.26%]
– 2 μl [13.3%] 2 μl [13.3%]
2 μl [0.0053%] 2 μl [0.0053%] –
2 μl [13.3%] 7 μl [46.6%] 2 μl [13.3%]
15 μl 15 μl 15 μl
Fig. 4. Characterization of hBMSCs on the siRNAmicroarray. (A) Phase-contrast cell-spot image after removing unattached cells (representative of n=4 array spots, scale bar= 100 μm).
(B) Immunoﬂuorescence image of hBMSCs-speciﬁcmarkers for conﬁrmation of hBMSCs characteristics after 72 h (representative of n=4array spots, scale bar=100 μm). The imagewas
obtained using an ImageXpress Ultra Point scanning confocal microscope with anti-CD105, anti-CD29, and anti-CD73 antibodies. Blue: nuclei stained with Draq5; green: ﬂuorescently
labeled antibodies targeting CD105 and CD29; red: ﬂuorescently labeled antibodies targeting CD73. Scrambled siRNA was used as a control.
371H.C. Kim et al. / Stem Cell Research 16 (2016) 365–376cells in each spot ranged from 30 to 60, and variations in cell numbers
did not affect the knockdown efﬁciency (Fig. 6).
3.4. The persistence of the gene silencing effect on the CDSM
Our data showed that a transfection time of 48 h was sufﬁcient for
gene knockdown on the CDSM. However, the persistence of the gene si-
lencing effect is also critical for functional genomics studies, particularlywhen combining gene knockdown with screening of compounds or in-
hibitors. Therefore, we examined the efﬁcacy of the siRNA knockdown
at 5 days after transfection with p65, Slug, and NCAD siRNAs. We con-
ﬁrmed the inhibition efﬁcacy after 5 days (Fig. 7), although the effect
is some decrease comparing with 48 h (Fig. 5 vs. 7; p65 12 vs. 32, Slug
9 vs. 43, N-cadherin 24 vs. 29 respectively). Also the silencing effect of
p65 siRNA persisted for 7 days though the efﬁciency was dramatically
decreased (data not shown). These data suggested that the siRNA
Table 2
The work ﬂow of printing solution condition for siRNA reverse transfection optimization.
Processing step Condition
Volume of siRNA
(concentration)
Kind of transfection
reagent/volume
Volume of sucrose (M) /gelatin (%) Volume of
Matrigela
Volume of
RNase-free watera,b
The time of reverse
transfection
Final conﬁrmed
optimization condition
Reference
Selection of transfection
reagent
2 μl [2.66 μM]
(20 μM)
Lipofectamine 2000,
Metafectene,
Metafectene PRO,
Turbofectine 8.0,
RNAi Max.
/2 μl
2 μl (0.8 M)/5 μl (0.8%)
[106 mM]/[0.26%]
2 μl 2 μl 48 h RNAi-Max Suppl. Fig. 3
Validation of transfection reagent
volume
2 μl (20 μM)
[2.5 μM] vs. 16 μl total vol.
[2.66 μM] vs. 15 μl total vol.
[2.85 μM] vs. 14 μl total vol.
RNAi-Max/3 μl, 2 μl, 1 μl 2 μl (0.8 M)/5 μl (0.8%)
[100 mM]/[0.25%] vs. 16 μl total vol.
[106 mM]/[0.26%] vs. 15 μl total vol.
[114 mM]/[0.28%] vs. 14 μl total vol.
2 μl 2 μl 48 h 2 μl RNAi Max Suppl. Fig. 4A
and B
Validation of sucrose and
gelatin
2 μl [2.66 μM]
(20 μM)
RNAi-Max/2 μl 2 μl (1.6 M) [213 mM]/5 μl (0.8%) [0.26%]
2 μl (0.8 M)[106 mM]/5 μl (0.8%) [0.26%]
2 μl (0.6 M)[80 mM]/5 μl (0.8%) [0.26%]
2 μl (0.6 M)[80 mM]/5 μl (0.4%) [0.13%]
2 μl 2 μl 48 h Sucrose:
2 μl (0.6 M)[80 mM]
Gelatin:
5 μl (0.4%) [0.13%]
Suppl. Fig. 4C
and D
Validation of siRNA volume and
reverse transfection time
2 μl [2.66 μM], 3 μl [3.75 μM]
4 μl [4.7 μM], 5 μl [5.55 μM]
(20 μM)
RNAi-Max/2 μl 2 μl (0.6 M)/5 μl (0.4%)
[80 mM]/[0.13%] vs. 15 μl total vol.
[75 mM]/[0.12%] vs. 16 μl total vol.
[70.58 mM]/[0.11%] vs. 17 μl total vol.
[66.66 mM]/[0.11%] vs. 18 μl total vol.
2 μl 2 μl 24 h
48 h
72 h
siRNA :
3 μl [3.75 μM]
Transfection
time: 48 h
Fig. 3
Suppl. Fig. 5
(): Stock concentration.
[]: Final concentration. The numbers from second places of decimals are ignored.
a The volume of Matrigel and RNase-free water is ﬁxed.
b RNase-free water is just used for total volume.
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373H.C. Kim et al. / Stem Cell Research 16 (2016) 365–376activity on CDSMwas optimal at 48 h after transfection and the activity
was detectable until 7 days but it is not recommendable time for effec-
tive screening.
Finally, we examined the effects of storage time on the CDSM.
Knockdown efﬁciency was maintained, albeit with a decrease over
time, for siRNA spots onCDSMs thatwere stored for 10days to 2months
at 4 °C (data not shown).Fig. 5.Effective inhibition of target genes after 48 h transfection inhBMSCs. (A) Anti-p65 labeled
quantitative analysis of the ratio of p65-positive cells. (B) Anti-Slug labeled immunoﬂuoresc
immunoﬂuorescence image and quantitative analysis of decreased expression of NCAD pr
expression by NCAD siRNA, and quantitative analysis of the ratio of β-catenin-positive cells. T
Blue: nuclei stained with Draq5; green: ﬂuorescently labeled antibodies against target protein
software. Each error bar represents the mean ± SD. ⁎p b 0.05, ⁎⁎⁎p b 0.001: statistical signiﬁcan4. Discussion
Gene or protein chips are common methods used for analyzing the
regulation of gene expression, genetic networks, and their pathways.
However, the quantity of mRNA often does not reﬂect the expression
of the proteins they correspond to, and the change of the expression
in protein often does not induce from mRNA.immunoﬂuorescence image for the conﬁrmation of p65 protein decrease byp65 siRNAand
ence image and quantitative analysis of decreased slug protein. (C) Anti-NCAD labeled
otein. (D) Anti-β-catenin labeled immunoﬂuorescence image of decreased β-catenin
he image was obtained using an ImageXpress Ultra Point scanning confocal microscope.
s. Scrambled siRNA was used as a control. The analysis was performed using MetaXpress
ce of comparisons with scramble siRNA (n= 6 array spots, scale bar =100 μm).
374 H.C. Kim et al. / Stem Cell Research 16 (2016) 365–376Therefore, in this study, we developed the CDSM method that
hBMSCs were attached to printed spots and evaluated knockdown
of target genes using the expression of the protein. This method is
expected to have applications in genome-wide loss-of-function.Fig. 6. The conﬁrmation ofmultispot siRNAmicroarray quality after 48 h transfection. (A) The anti-
of four kinds siRNA. The image shows the localization of the spots for scramble, p65, GFP andNCAD
(B)Quantitative scatter analysis andnormalized results of theNCAD-positive cell ratios and cell num
acquired by an ImageXpress Ultra Point scanning confocalmicroscopewith anti-NCAD antibodies.
was used as a control. Each error bar represents the mean ± SD. ⁎⁎⁎p b 0.001: statistical signiﬁcanCell-based siRNA microarrays have made it possible to analyze phe-
notypic changes in cells, including increases or decreases in cellular
products and variations in cell morphology. Such methods also provide
advantages over conventional methods, such as well-based screening,NCAD immunoﬂuorescence image of NCAD protein inhibited expression from themultispots
siRNA. All siRNA spotswere printed in 32 spots each using two pins (for a total of 128 spots).
bers shown in (A) (representative ofn=32array spots, scale bar=100 μm). The imagewas
Blue: Draq5 for the nucleus, green:ﬂuorescently labeled anti-NCAD antibody. Scramble siRNA
ce for the comparison with scramble siRNA.
375H.C. Kim et al. / Stem Cell Research 16 (2016) 365–376which requires high numbers of cells, large-scale and time consuming. In-
deed, ourmicroarray system allowed the printing of up to 3888 spots per
slide, permitting screening of the entire genome with only 5–7 microar-
ray slides (Genovesio et al., 2011a, 2011b). Moreover, in our current
CDSM method, we overcame the limitation of using actively mobile
cells, such as hBMSCs, which were previously found to migrate outside
of the spot area, spreading to other spots. Additionally,many investigators
have already pursued new strategies for minimizing the spreading phe-
nomenon in microarrays, such as poly-N-isopropylacrylamide (PNI)
micropatterning (Zhang et al., 2011). These methods require severalFig. 7. Veriﬁcation of the persistence of gene expression silencing. (A) Immunoﬂuorescence im
(B) Quantitative analysis of p65-, Slug-, and NCAD-positive cell ratios and cell numbers from
images were acquired using an ImageXpress Ultra Point scanning confocal microscope with a
ﬂuorescence-labeled antibody targeting the appropriate protein. Scramble siRNA was used a
represent means ± SDs. ⁎⁎p b 0.01, ⁎⁎⁎p b 0.001: statistical signiﬁcance in comparison with scrsteps, including polymer coating and removal by controlling the temper-
ature, and have mostly been applied in cancer cell lines, with few studies
reporting hBMSC-based microarrays. It is generally considered challeng-
ing to apply mesenchymal cells to large-scale cell imaging methods for
analysis of genetic functions and signal pathways using siRNA. We
showed that high-efﬁciency, persistent siRNA knockdown could be
achieved in hBMSCs, with only 30–60 cells per spot and with no require-
ment for additional subculture of hBMSCs. These results suggested that
this approach might have applicability in a variety of assays, including
screening with combinations of compounds, protein inhibitors, viruses,ages of knockdown of p65, Slug, and NCAD by siRNA after 5 days of reverse transfection.
data in (A) (lower panel) (representative of n= 6 array spots, scale bar =100 μm). The
nti-p65, anti-Slug, and anti-NCAD antibodies. Blue: Draq5 for detection of nuclei, green:
s a control. The analysis was performed with MetaXpress software. Bars and error bars
amble siRNA.
376 H.C. Kim et al. / Stem Cell Research 16 (2016) 365–376and double immunoﬂuorescent probes. The sustained activity of printed
siRNA spots (2months when stored at 4 °C) offers opportunity for repeat
screening and variations in experimental setups. Thus, this CDSMmethod
represents a qualitatively improved siRNA microarray screening method
for hBMSCs.
5. Conclusions
Gene networks in hBMSCs are critical for understanding of their
function; the CDSMmethod for functional genomic analysis is expected
to contribute for more efﬁcient genomic research.
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